Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2020 Net Income-$86.22M-$86.22MN/M vs Q2 2020 EPS Diluted-$1.41-$1.41N/M vs Q2 2020 Operating Income-$91,222,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$117,543,000N/M ended Jun 30, 2021 · filed Jul 29, 2021 · 29 d after period end